Bruker Corporation (NASDAQ:BRKR) Given Average Recommendation of “Hold” by Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been given an average recommendation of “Hold” by the fifteen research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $50.5385.

A number of brokerages have issued reports on BRKR. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a report on Friday, May 8th. Barclays raised their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citigroup raised their target price on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, TD Cowen raised their target price on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th.

Insider Activity at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 27.20% of the company’s stock.

Institutional Investors Weigh In On Bruker

Large investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Bruker during the fourth quarter valued at approximately $26,000. Allworth Financial LP increased its stake in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the period. Spire Wealth Management increased its stake in shares of Bruker by 85.3% during the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 665 shares during the period. Finally, Summit Securities Group LLC acquired a new position in shares of Bruker during the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

Shares of BRKR stock opened at $42.75 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. Bruker has a one year low of $28.53 and a one year high of $56.22. The company’s 50-day simple moving average is $37.83 and its 200-day simple moving average is $42.30. The stock has a market capitalization of $6.51 billion, a price-to-earnings ratio of -178.13, a PEG ratio of 2.57 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter last year, the company posted $0.47 earnings per share. Bruker’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be paid a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.